3 terminated, 1 unknown, 1 withdrawn. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Unknown 1 |
Follow pidilizumab: new trials by email Literature Review of pidilizumab trials Research Report on pidilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma lenalidomide, pidilizumab, pharmacological study - Multiple Myeloma | Phase 1 | Terminated | Ohio State University Comprehensive Cancer Center | 20 | 2014-03-03 | 2023-01-27 |
| Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma MDV9300 - DIPG | Phase 1 / Phase 2 | Unknown | Hadassah Medical Organization | 50 | 2014-02-01 | 2016-09-13 |
| CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors p53: 264-272 peptide, CT-011 - Breast Cancer, Colon Cancer | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2011-06-15 | 2017-07-02 | |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma CT-011 - Primary Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | CureTech Ltd | 2 | 2009-10-01 | 2012-10-23 |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection CT-011 - Chronic Hepatitis C | Phase 1 / Phase 2 | Terminated | CureTech Ltd | 13 | 2009-09-01 | 2014-08-29 |
Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Hepatitis C, Chronic (1) · Liver Diseases (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1)
CureTech Ltd (2) · Hadassah Medical Organization (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1)
Israel (3) · United States (2)
Yaron Ilan, MD (2) · Yvonne Efebera (1)